Tarsus Pharmaceuticals, Inc.
TARSHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tarsus Pharmaceuticals, Inc. focuses on Biotechnology services and products. Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. Valued at $3.19B, TARS is a mid-cap name in its sector. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites.
Market Cap
$3.19B
Beta
0.45
P/E (TTM)
—
P/E (Fwd)
-136.40
EPS (TTM)
$-1.02
EPS (Fwd)
$-0.50
ROE
-13.7%
ROA
-5.5%
Cash
$449.7M
Total Debt
$88.8M
Free CF
$67.5M
52W Change
3.2%
Annual Financials
Cash vs Debt
Where TARS stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, TARS finished 1.26% above its 150-day moving average ($67.22) and 0.07% below its 200-day moving average ($68.12). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TARS overbought or oversold?
At the October 19, 2026 close, TARS's RSI(14) was 30.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $449.7M in cash and $88.8M in debt, TARS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $67.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -13.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $25.8M (2022) to $451.4M (2025), reflecting a 1648% increase over the period.
With a beta below 0.7, Tarsus Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, TARS has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Tarsus Pharmaceuticals, Inc. and its sector.